U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H19N3
Molecular Weight 265.3529
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIRTAZAPINE

SMILES

CN1CCN2C(C1)C3=C(CC4=C2N=CC=C4)C=CC=C3

InChI

InChIKey=RONZAEMNMFQXRA-UHFFFAOYSA-N
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

HIDE SMILES / InChI

Molecular Formula C17H19N3
Molecular Weight 265.3529
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Mirtazapine, originally known as ORG 3770, was first synthesized by the Department of Medicinal Chemistry of NV Organon in the Netherlands (Kaspersen et al. 1989). First approved for use in major depression in the Netherlands in 1994, mirtazapine was introduced in the United States in 1996. The antidepressant mirtazapine has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors. It enhances, therefore, the release of norepinephrine and 5-HT1A-mediated serotonergic transmission. This dual mode of action may conceivably be responsible for mirtazapine's rapid onset of action.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
7.0 null [pKi]
8.62 null [pKi]
8.1 null [pKi]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
REMERON

Cmax

ValueDoseCo-administeredAnalytePopulation
32.3 μg/L
15 mg single, oral
MIRTAZAPINE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
345 μg × h/L
15 mg single, oral
MIRTAZAPINE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
21.2 h
15 mg single, oral
MIRTAZAPINE plasma
Homo sapiens
30 h
15 mg single, oral
MIRTAZAPINE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
15%
15 mg single, oral
MIRTAZAPINE plasma
Homo sapiens
15%
15 mg single, oral
MIRTAZAPINE plasma
Homo sapiens

Doses

AEs

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
The recommended starting dose for REMERON® (mirtazapine) Tablets is 15 mg/day, administered in a single dose. In the controlled clinical trials establishing the efficacy of REMERON in the treatment of major depressive disorder, the effective dose range was generally 15 to 45 mg/day.
Route of Administration: Oral
In Vitro Use Guide
0.1 uM mirtazapine affects glucocorticoid receptors expression (U937 cells)
Substance Class Chemical
Record UNII
A051Q2099Q
Record Status Validated (UNII)
Record Version